Systemic Infection Treatment Market

The global systemic infection treatment market was valued at USD 15.2 billion in 2025 and is estimated at USD 16.2 billion in 2026. The market is projected to reach USD 26.6 billion by 2034, representing a 6.4% CAGR during 2026–2034.

Systemic infection treatment covers pharmaceutical therapy for infections that extend beyond a local site and may involve the bloodstream, multiple organs or severe systemic inflammatory response. The revenue pool spans antibacterial, antiviral and antifungal medicines used across hospital and outpatient pathways, with the highest clinical and commercial intensity concentrated in severe infections requiring intravenous therapy, combination regimens or prolonged monitoring.

Antimicrobial resistance is changing the mix of value rather than simply expanding antibiotic volume. WHO reported in 2025 that one in six laboratory-confirmed bacterial infections causing common infections in 2023 was resistant to antibiotics and that resistance increased in more than 40% of monitored pathogen-antibiotic combinations between 2018 and 2023. This raises the commercial importance of rapid susceptibility testing, stewardship and access to effective Watch and Reserve therapies for resistant disease.

At the same time, stewardship policies constrain indiscriminate use of broad-spectrum agents. WHO’s global target calls for at least 70% of antibiotic use to come from the Access group by 2030. Manufacturers therefore face a market in which clinical differentiation, resistant-pathogen activity, label expansion and hospital access can support premium value, while mature agents remain exposed to generic pricing and utilization controls.

Source: WHO — Sepsis fact sheet; WHO — Global antibiotic resistance warning; WHO — Antibiotic use and AWaRe analysis.

The study covers prescription pharmaceutical treatment of systemic bacterial, viral and fungal infections across severity, patient group, care setting and therapeutic-class dimensions.

Sepsis burden sustains high-acuity treatment demand

WHO cites 48.9 million sepsis cases and 11 million sepsis-related deaths worldwide in the most widely used global burden estimate. Severe systemic infections therefore remain a high-priority hospital treatment area with substantial mortality and resource use.

Source: World Health Organization.

Antimicrobial resistance shifts value toward effective regimens

WHO reported that one in six laboratory-confirmed bacterial infections in 2023 was resistant to antibiotic treatment, raising the clinical value of agents and combinations able to address resistant pathogens.

Source: World Health Organization.

Stewardship limits indiscriminate broad-spectrum use

The global 2030 target calls for at least 70% of human antibiotic use to come from Access-group antibiotics. This policy direction favors appropriate narrow-spectrum selection where possible and reserves higher-risk agents for clinically justified cases.

Source: World Health Organization.

Hospital-acquired and device-associated infections raise treatment complexity

Patients with invasive devices, surgery, intensive-care exposure or immunosuppression can require prolonged and combination therapy, increasing drug intensity while also strengthening demand for diagnostics and infection-control measures.

Generic maturity creates price pressure in established classes

Many foundational anti-infectives are generic, so value growth depends more on resistant-infection activity, improved dosing, formulation convenience and new combinations than on broad price increases across mature molecules.

New beta-lactam and beta-lactamase inhibitor combinations target resistant Gram-negative infections

The U.S. FDA approved EMBLAVEO, aztreonam and avibactam, in February 2025 for adults with complicated intra-abdominal infections with limited or no treatment options, reinforcing innovation around resistant Gram-negative pathogens.

Source: AbbVie/FDA approval announcement.

AWaRe-based stewardship is becoming a commercial planning variable

Manufacturers and health systems increasingly need to position anti-infectives within Access, Watch and Reserve principles, linking sales strategy to resistance risk and evidence-based use rather than simple prescription growth.

Source: World Health Organization.

Rapid diagnostics increasingly influence therapy choice

Faster organism identification and susceptibility testing can shorten empirical broad-spectrum use and redirect demand toward targeted agents, increasing the importance of diagnostic-treatment integration.

Combination therapy remains important in severe and resistant disease

Complex systemic infections often require multi-drug strategies while microbiology is clarified or when resistance mechanisms limit single-agent options. This supports combination products and hospital protocols built around coverage gaps.

Access and stewardship must improve together

WHO notes that some settings overuse Watch antibiotics while others have poor access even to Reserve antibiotics needed for resistant infections. Commercial expansion therefore depends on balanced access rather than unrestricted antibiotic volume.

Source: World Health Organization.

Hospital formularies concentrate purchasing decisions

Antimicrobial stewardship committees, infectious-disease specialists and pharmacy teams can strongly influence formulary placement, sequencing and restriction criteria, making clinical evidence and resistance coverage essential for adoption.

Reimbursement pressure differs by treatment setting

High-cost branded agents for resistant infections face payer and hospital budget scrutiny, while inexpensive generics dominate uncomplicated systemic infections. Value arguments increasingly emphasize avoided treatment failure, shorter hospitalization and effective resistant-pathogen coverage.

Type segmentation separates the major pathogen-directed treatment categories.

Antibacterial — Leading Segment

Antibacterials represent the largest revenue base because bacterial sepsis, bloodstream infection, pneumonia, urinary infection and intra-abdominal infection generate substantial systemic treatment demand.

Antiviral — Established Growth Segment

Antiviral demand is supported by systemic viral diseases, immunocompromised patients and continued innovation in targeted oral and parenteral therapies.

Antifungal — High-Acuity Niche

Systemic antifungals serve smaller patient populations but can carry high clinical and economic intensity in invasive disease, transplantation, oncology and critical care.

Care setting determines treatment intensity, route of administration and monitoring requirements.

Hospitals — Leading Application

Hospitals lead because severe infections, sepsis and resistant pathogens often require intravenous therapy, cultures, imaging, intensive monitoring and multi-disciplinary management.

Clinics — Ambulatory Treatment Base

Clinics manage stable systemic infections and follow-up care where oral or scheduled parenteral therapy can be delivered outside inpatient settings.

Others — Specialized Care Settings

Other settings include infusion centers, long-term care and home-based programs operating under local prescribing and monitoring rules.

Age strongly affects infection risk, pharmacology, comorbidities and treatment intensity.

Adult Patients — Largest Volume Base

Adults represent the broadest treated population across community and hospital infections.

Pediatric Patients — Distinct Dosing Segment

Pediatric therapy requires age- and weight-specific dosing, formulation suitability and careful safety assessment.

Geriatric Patients — High-Acuity Growth Segment

Older adults carry elevated risk from comorbidity, frailty, hospitalization and immune decline, increasing the need for systemic anti-infective treatment and monitoring.

Severity drives route, site of care, treatment breadth and drug cost.

Mild — Lower-Intensity Segment

Mild systemic infections can often be managed with oral therapy and closer stewardship of broad-spectrum exposure.

Moderate — Escalation Segment

Moderate infections may require parenteral therapy, additional diagnostics or short hospitalization depending on organism and patient risk.

Severe — Highest Clinical Intensity

Severe infection and sepsis require urgent therapy, source control and monitoring; resistant cases can generate the highest per-patient drug value.

Drug-class choice balances coverage breadth with resistance stewardship.

Broad-Spectrum — Core Empirical Therapy

Broad-spectrum agents remain important before organism and susceptibility data are available, particularly in severe disease, but face stronger stewardship pressure.

Narrow-Spectrum — Stewardship-Aligned Segment

Targeted agents support de-escalation once the pathogen is known and align with efforts to reduce unnecessary resistance pressure.

Combination Therapies — Resistant-Infection Opportunity

Combination approaches can overcome resistance mechanisms or fill coverage gaps and are increasingly important in difficult Gram-negative and polymicrobial infections.

North America leads through high hospital spending, advanced microbiology capability, broad access to branded and generic anti-infectives and active development of therapies for resistant infections.

Europe combines mature anti-infective use with strong stewardship and procurement discipline. Reimbursement and national antibiotic policies shape access to premium agents.

Large populations, rising hospital capacity and substantial infectious-disease burden support growth, while resistance surveillance and affordability vary widely among countries.

Urban hospital systems generate demand for modern anti-infectives, but reimbursement and public-sector budgets can delay uptake of premium branded agents.

Systemic infection burden is significant, but diagnostic capacity and access to the full range of essential and Reserve antibiotics remain uneven across markets.

Research-based leaders compete on resistant-pathogen innovation

Large pharmaceutical companies focus higher-value R&D on differentiated anti-infectives, novel mechanisms and combinations where unmet need supports premium positioning.

Generic manufacturers dominate mature volume classes

Established penicillins, cephalosporins and other mature agents face intense generic competition, with manufacturing scale and hospital tender economics central to share.

Hospital access requires stewardship-compatible evidence

Commercial success increasingly depends on demonstrating where a new agent fits within stewardship pathways, resistant-organism treatment and formulary restriction criteria.

Portfolio breadth supports institutional relationships

Companies with oral, intravenous, branded and generic anti-infective portfolios can compete across treatment stages and care settings, although individual product access remains protocol-dependent.

The following companies are covered in the competitive analysis and company-profile framework of the syndicated report.

• Pfizer Inc.
• Merck & Co., Inc.
• GSK plc
• Johnson & Johnson
• Novartis AG
• F. Hoffmann-La Roche Ltd
• AstraZeneca PLC
• Sun Pharmaceutical Industries Ltd.
• Wockhardt Limited
• Viatris Inc.
• Abbott Laboratories
• Bayer AG
• Sanofi
• Teva Pharmaceutical Industries Ltd.

The systemic infection treatment market is projected to grow from USD 16.2 billion in 2026 to USD 26.6 billion by 2034. Revenue growth will increasingly depend on treatment of resistant and severe infections, while stewardship and generic pricing moderate volume-led expansion in mature classes.

The systemic infection treatment market study combines top-down market reconciliation with bottom-up analysis of product categories, end-use demand, company participation and country-level commercial conditions. Secondary research draws on regulators, public-health agencies, professional bodies, peer-reviewed literature, official statistics and primary company disclosures, while primary research is used to test market boundaries, channel structure, pricing behavior and adoption assumptions.

Historical and current evidence is reconciled against the report segmentation so that the 2025 base year, 2026 estimate and 2034 forecast use consistent definitions. Forecast assumptions consider underlying demand indicators, clinical or operational adoption, regulatory change, competitive intensity, procurement behavior, pricing pressure and regional access conditions rather than extending a single historical trend mechanically.

Where products have multiple clinical or non-clinical uses, revenue is allocated only to the uses included in this market definition; total company or product sales are not treated as target-market revenue without an explicit indication or use split.